The Division of Hematology & Oncology

• Benign and malignant hematology and solid tumor oncology
• Clinical trials that include novel agents or experimental regimens
• High-dose chemotherapy
• Autologous and Allogeneic stem cell transplantation
• Target therapy and immunotherapy

The Division, with its colleagues in other medical specialties, forms the Chang-Gung Memorial Hospital Cancer Center in Chiayi, one of the leading cancer treatment and research facilities in southern part of Taiwan. Our faculty interacts closely with physicians in other departments, including Diagnostic Radiology, Surgery, Radiation Oncology, and Pathology. This close collaboration assures unsurpassed patient care, from diagnosis to staging to decisions incorporating the best therapy. The division prides itself on multidisciplinary approach to tackle the most difficult and complex cancers.

The facilities of the Division includes outpatient clinics, inpatient wards, infusion units, stem cell procurement unit, bone marrow transplant units, clinical trial office and hematology laboratory.

The Division provides a full breadth of clinical and support services to patients, family members, and friends through a variety of multidisciplinary clinical programs focused on specific types of cancer. In order to provide the best possible care to the patient, the patient's evaluation and treatment is managed by members of individual multidisciplinary clinical cancer programs that are organized by cancer diagnosis. The participation of patients in these multidisciplinary programs assures patient access to national, multi-institutional clinical trials as well as those developed and exclusively offered by the Division.

Research is also an essential part of the Division's mission. For years, we have been involved in clinical and basic research related to cancer. We conduct research into the causes and mechanisms of cancer, with an emphasis on translating that work to clinical application, so that we can offer patients the benefits of these advances. Research interests include exploring fundamental pathways which are critically altered in tumor cells, cancer stem cells, and the roles of circulating endothelial cells (CEC) and circulating progenitor cells (CPC) in cancer biology. The Division also enjoyed its groundbreaking success on the pleuripotency and plasticity of mesenchymal stem cells (MSC).

Aside from our own fruitful research work, we also collaborate with researchers from Chang-Gung University, National Chung Cheng University, and National Health Research Institutes. There is a continuous exchange of ideas between investigators who pursue related issues in cancer biology.

Our team includes 4 board-certified medical oncologists and hematologists, 3 nurse care coordinators, 2 laboratory technicians, and 2 research nurse coordinators. To further expand our service, we hope to recruit more experts specialized in cancer care and research to join us in the near future.